They found that the enzyme may prevent a stiff heart through activating the gene ... of heart failure," Yoshida summarized. "HFpEF is a growing global concern due to limited drug therapy options.
A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficacy in a phase 1 trial.
Bayer’s AskBio unit has reported the first clinical data for its congestive heart failure gene therapy, showing preliminary signs of efficacy with no serious adverse events linked to the treatment.
New Computational Method Reveals Congestive Heart Failure Feb. 6 ... issues for Black and Hispanic ... Link Between Gene Duplications and Deletions Within Chromosome Region and Nonsyndromic ...
PDE2 (phosphodiesterase 2) is upregulated in human heart failure. Cardiac PDE2‐transgenic mice are ... function and its putative beneficial effects in HF, we performed gene therapy with ...
GP-531 is under clinical development by ViCardia Therapeutics and currently in Phase II for Congestive Heart Failure (Heart Failure ... focuses on developing a therapy that reverses the progression of ...
Although reperfusion therapy is currently the main therapeutic strategy, the risk of progression to adverse cardiac remodeling and subsequently heart failure (HF ... phenotype by repressing ...
Sepsis is an abnormal, life-threatening response to infection that leads to (multi-)organ dysfunction and failure ... of novel diagnostic gene expression signatures (e.g., cellular reprogramming) that ...
"We believe the next evolution in treating HPP will be a gene therapy in which a single injected dose will provide a lifelong treatment for patients," said Millán. In a paper published in the ...
Now scientists have discovered a dormant gene that could be reactivated to regenerate heart tissue, preventing the progression to heart failure. After a heart attack, scar tissue often forms to ...